ArticleCardiovascular intervention and therapeutics2026
Cardiac damage stages at follow-up and subsequent clinical outcomes in patients with severe aortic stenosis.
Article in Cardiovascular intervention and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
43 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Data on the impact of cardiac damage based on follow-up echocardiography at 1 year in patients with severe aortic stenosis (AS) are insufficient. The current study included 1991 patients with severe AS who underwent follow-up echocardiography at 1 year after the initial AVR strategy (n = 1211) and conservative management (n = 780) in the CURRENT AS Registry-2. In the initial AVR group, the higher adjusted risk for stage 1, 2, and 3 or 4 relative to stage 0 was not significant for the primary outcome (a composite of all-cause death or hospitalization for heart failure) (hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.25-1.04; HR = 0.71, 95% CI = 0.39-1.29; and HR = 0.57, 95% CI = 0.22-1.48). Meanwhile, in the conservative management group, it was significant for the primary outcome (HR = 2.33, 95% CI = 0.99-5.52; HR = 2.89, 95% CI = 1.30-6.40; and HR = 6.44, 95% CI = 2.62-15). A significant association was observed between the initial treatment strategies and effects of cardiac damage stages at 1 year on the primary outcome (P interaction = 0.003). Cardiac damage stages based on follow-up echocardiography at 1 year were useful for prognostic stratification in patients who received conservative management, but not in those who underwent initial AVR. UMINID: UMIN000034169.
Indexed as
Identifiers
42192088What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.